Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions such as cancer, heart disease, diabetes, and mental illnesses. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic use.

Statistics:

The global Epigenetic Drugs And Diagnostic Technologies Market is estimated to account for US$ 28,606.6 Mn in terms of 2027.

Global Epigenetic Drugs and Diagnostic Technologies Market: Drivers

Approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. For instance, in January 2020, the U.S. Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/epigenetics-drugs-and-diagnostic-technologies-market-4026

Global Epigenetic Drugs and Diagnostic Technologies Market: Opportunities

Adoption of Artificial Intelligence (AI) for R&D in epigenetic drugs is expected to offer lucrative growth opportunities for players in the global epigenetic drugs and diagnostic technologies market. Epigenetic drug targets are particularly suited for AI studies. The use of AI in pre-clinical drug discovery offers the potential to reduce the cycle time for lead identification.

Global Epigenetic Drugs and Diagnostic Technologies Market: Restraints

Unique reactions of each patient to drugs leads to various challenges for the scientists and researchers studying genomic alterations and their phenotypic expression, which is expected to hinder growth of the market.

Key Takeaways:

The global epigenetic drugs and diagnostic technologies market was valued at US$ 6,800.3 Mn in 2019 and is forecast to reach a value of US$ 28,606.6 Mn by 2027 at a CAGR of 19.7% between 2020 and 2027. Increasing approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period.

Epigenetic Drugs segment held dominant position in the global epigenetic drugs and diagnostic technologies market in 2019, accounting for 71.5% share in terms of value, increasing prevalence of cancer is expected to propel growth of the segment during the forecasted period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4026

Market Trends

Players in the market are focused on R&D of new drugs to expand their product portfolio. For instance, in July 2020, Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics for R&D of novel therapies, presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020.

Major players in the market are also focused on raising funds for R&D of new technologies. For instance, in June 2020, Base Genomics, an epigenetics company, raised US$ 11 million to progress development of its TAPS technology, a novel chemical reaction that converts methylated cytosine to thymine under mild conditions.

Global Epigenetic Drugs and Diagnostic Technologies Market: Competitive Landscape

Major players operating in the global epigenetic drugs and diagnostic technologies market include, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.

Global Epigenetic Drugs and Diagnostic Technologies Market: Key Developments

June 2020: Epizyme, Inc. received the U.S. Food and Drug Administration’s supplemental New Drug Application approval for TAZVERIK (tazemetostat) for the following two distinct follicular lymphoma indications.

March 2018: EpiGentek announced its technological and financial support for new skincare startup EpigenCare for development and commercialization of a personalized skincare test based on epigenetic markers.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4026

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737